Technology
Health
Pharmaceutical

Allena Pharmaceuticals

$7.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.38 (-5.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALNA and other stocks, options, ETFs, and crypto commission-free!

About

Allena Pharmaceuticals, Inc. Common Stock, also called Allena Pharmaceuticals, is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Read More Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.

Employees
Headquarters
Newton, Massachusetts
Founded
2011
Market Cap
158.15M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
73.15K
High Today
$7.77
Low Today
$7.12
Open Price
$7.67
Volume
20.58K
52 Week High
$17.56
52 Week Low
$4.80

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2017 IPO
US

News

Seeking AlphaMar 13

Allena Pharmaceuticals (ALNA) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this event. 1 26 Click to enlarge Notes:...

30
MarketBeatMar 10

Stock Price, News, & Analysis for Allena Pharmaceuticals

News headlines about ALNA stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10,...

2
Markets InsiderMar 7

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

-- Achieved Alignment with U.S. Food and Drug Administration (FDA) on Phase 3 URIROXTM Program and Accelerated Approval Strategy for Reloxaliase -- -- Phase 3 URIROX-1 and URIROX-2 Trials Ongoing; URIROX-1 Topline Data Expected in Second Half of 2019 -- -- Louis Brenner, M.D. Appointed Chief Executive Officer -- -- Multiple Catalysts Expected Across Pipeline in 2019 -- NEWTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company...

35

Earnings

-$0.58
-$0.51
-$0.45
-$0.38
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.46 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.